Sai Life Sciences (NSE:SAILIFE) Other Long-Term Liabilities: ₹ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
21 GF Score
Price ₹1,600.50
! 4 Warning Signs
View Full Analysis

What is Sai Life Sciences Other Long-Term Liabilities?

Sai Life Sciences NSE:SAILIFE +3.55% 21 Other Long-Term Liabilities is ₹ Mil as of Jun. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Sai Life Sciences's other long-term liabilities for the quarter that ended in Jun. 2026 was ₹ Mil.

Sai Life Sciences's quarterly other long-term liabilities increased from Dec. 2025 (₹ Mil) to Mar. 2026 (₹71 Mil) but then declined from Mar. 2026 (₹71 Mil) to Jun. 2026 (₹ Mil).

Sai Life Sciences's annual other long-term liabilities increased from Mar. 2024 (₹61 Mil) to Mar. 2025 (₹64 Mil) and increased from Mar. 2025 (₹64 Mil) to Mar. 2026 (₹71 Mil).

Sai Life Sciences Other Long-Term Liabilities Related Terms

Sai Life Sciences Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Other Long-Term Liabilities Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
72.91 76.11 60.93 63.51 70.80

Sai Life Sciences Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial - 300.25 - 70.80 -
NSE:SAILIFE
21GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹ Mil mean?
Sai Life Sciences (NSE:SAILIFE) has a Other Long-Term Liabilities of ₹ Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sai Life Sciences and its competitors.
Is Sai Life Sciences' Other Long-Term Liabilities too high?
Sai Life Sciences' current Other Long-Term Liabilities is ₹ Mil. Overall, Sai Life Sciences has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Other Long-Term Liabilities compare to TMO and DHR?
Sai Life Sciences' Other Long-Term Liabilities of ₹ Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current Other Long-Term Liabilities is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Other Long-Term Liabilities of ₹ Mil. The current Other Long-Term Liabilities is ₹ Mil. Sai Life Sciences' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Other Long-Term Liabilities is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
21GF Score

Get the complete analysis for NSE:SAILIFE

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,600.50
Price